57 completed, 15 terminated, 3 unknown, 3 withdrawn. 42 Phase 2, 35 Phase 1, 9 Not applicable, 1 Early Phase 1, 1 Phase 3.
Follow Male Breast Cancer: new trials by email Literature Review of Male Breast Cancer trials Research Report on Male Breast Cancer
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Male breAsT cAncer preDisposition Factor: Creation of a Control Cohort 2 Questionnaire completion, Genetic analysis (WES) - Male Breast Cancer | Not applicable | Not yet recruiting | Institut Claudius Regaud | 120 | 2026-10-15 | 2026-08-19 |
| ETHAN - ET for Male BC Tamoxifen, Anastrozole, Degarelix - Male Breast Cancer, Hormone Receptor-positive Breast Cancer | Phase 2 | Recruiting | Jose Pablo Leone | 60 | 2023-10-11 | 2026-08-24 |
| Testosterone & Tamoxifen Trial AndroGel - Male Breast Cancer | Not applicable | Terminated | University Medical Center Groningen | 5 | 2022-11-10 | 2024-08-09 |
| EORTC Quality of Life Measurement in Males With Breast Cancer structured Interview - Male Breast Cancer, Quality of Life | Completed | Helios University Hospital Wuppertal | 65 | 2019-11-01 | 2026-03-27 | |
| Pilot Study of Paclitaxel Plus Pembrolizumab in Metastatic HER2-Negative Breast Cancer Pembrolizumab, Paclitaxel - Breast - Female, Male Breast Cancer | Phase 2 | Completed | Wake Forest University Health Sciences | 40 | 2017-06-12 | 2023-08-04 |
| Silent Breast Cancer A Study of the Disease Prevalence Held by Imaging Guided Biopsies in Autopsy Specimens Bilateral mastectomy, Biopsy - Female Breast Cancer, Male Breast Cancer | Not applicable | Unknown | Centro Hospitalar Lisboa Ocidental | 768 | 2016-09-01 | 2017-11-28 |
| CYP17 Lyase and Androgen Receptor Inhibitor Treatment With Seviteronel Trial (INO-VT-464-006; NCT02580448) Seviteronel - Cancer of the Breast, Breast Cancer | Phase 1 / Phase 2 | Completed | Innocrin Pharmaceutical | 175 | 2015-08-01 | 2019-02-01 |
| Romidepsin and Abraxane in Treating Patients With Metastatic Inflammatory Breast Cancer Romidepsin, Abraxane - HER2-negative Breast Cancer, Inflammatory Breast Cancer | Phase 1 / Phase 2 | Terminated | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | 9 | 2014-04-01 | 2025-05-16 |
| Ganetespib, Paclitaxel, Trastuzumab and Pertuzumab for Metastatic Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer ganetespib, paclitaxel, trastuzumab - HER2-positive Breast Cancer, Male Breast Cancer | Phase 1 | Completed | Memorial Sloan Kettering Cancer Center | 9 | 2014-04-01 | 2018-06-14 |
| Propranolol Hydrochloride in Treating Patients With Locally Recurrent or Metastatic Solid Tumors That Cannot Be Removed By Surgery propranolol hydrochloride, Correlative Studies - Male Breast Cancer, Recurrent Melanoma | Early Phase 1 | Completed | William Carson | 1 | 2014-01-21 | 2022-12-06 |
| Understanding Male Breast Cancer: Salah Azaïz Cancer Institute Experience Male Breast Cancer | Unknown | Salah Azaïz Cancer Institute | 150 | 2014-01-01 | 2017-08-07 | |
| Omega-3 Fatty Acid in Treating Patients With Stage I-III Breast Cancer omega-3 fatty acid, placebo, laboratory biomarker analysis - Ductal Breast Carcinoma in Situ, Lobular Breast Carcinoma in Situ | Phase 2 | Completed | Wake Forest University Health Sciences | 57 | 2013-11-01 | 2019-10-30 |
| Carboplatin, Gemcitabine Hydrochloride, and Mifepristone in Treating Patients With Advanced Breast Cancer or Recurrent or Persistent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer mifepristone, carboplatin, gemcitabine hydrochloride - Male Breast Cancer, Recurrent Breast Cancer | Phase 1 | Completed | University of Chicago | 31 | 2013-11-01 | 2018-09-11 |
| Lapatinib Ditosylate and Radiation Therapy in Treating Patients With Locally Advanced or Locally Recurrent Breast Cancer lapatinib ditosylate, radiation therapy, laboratory biomarker analysis - Male Breast Cancer, Recurrent Breast Cancer | Phase 2 | Terminated | Stanford University | 7 | 2013-07-01 | 2017-06-26 |
| Phase 1b/2 Trial Using Lapatinib, Everolimus and Capecitabine for Treatment of HER-2 Positive Breast Cancer With CNS Metastasis lapatinib ditosylate, everolimus, capecitabine - Central Nervous System Metastases, HER2-positive Breast Cancer | Phase 1 / Phase 2 | Completed | Jonsson Comprehensive Cancer Center | 9 | 2013-06-26 | 2019-11-12 |
| 18F-FPPRGD2 PET/CT or PET/MRI in Predicting Early Response in Patients With Cancer Receiving Anti-Angiogenesis Therapy 18F-fludeoxyglucose (18F-FDG), 18F-FPPRGD2 - Adult Giant Cell Glioblastoma, Adult Glioblastoma | Phase 1 / Phase 2 | Completed | Sanjiv Sam Gambhir | 25 | 2013-03-04 | 2019-10-03 |
| Vaccine Therapy in Treating Patients With Stage IV Hormone Receptor Positive Breast Cancer HER-2/neu peptide vaccine - HER2-positive Breast Cancer, Male Breast Cancer | Phase 2 | Terminated | University of Washington | 3 | 2012-12-01 | 2017-04-11 |
| A Pilot Study of Irinotecan in Patients With Breast Cancer and CNS Metastases irinotecan hydrochloride, laboratory biomarker analysis - Central Nervous System Metastases, Male Breast Cancer | Not applicable | Withdrawn | University of California, Irvine | 2012-12-01 | 2014-10-08 | |
| Vorinostat in Treating Patients With Stage IV Breast Cancer Receiving Hormone Therapy vorinostat, anastrozole, letrozole - Male Breast Cancer, Recurrent Breast Cancer | Not applicable | Completed | University of Washington | 15 | 2012-11-01 | 2020-01-07 |
| Akt Inhibitor MK2206, Lapatinib Ditosylate, and Trastuzumab in Treating Patients With Locally Advanced or Metastatic HER2-Positive Breast , Gastric, or Gastroesophageal Cancer That Cannot Be Removed By Surgery Akt inhibitor MK2206, trastuzumab, lapatinib ditosylate - Adenocarcinoma of the Gastroesophageal Junction, HER2-positive Breast Cancer | Phase 1 | Terminated | National Cancer Institute (NCI) | 60 | 2012-09-01 | 2013-09-30 |
Showing 20 of 80. Sign in to see all of them.
Breast Neoplasms, Male (80) · Breast Neoplasms (74) · Carcinoma, Ovarian Epithelial (8) · Colonic Neoplasms (8) · Rectal Neoplasms (7) · Carcinoma, Non-Small-Cell Lung (6) · Carcinoma, Renal Cell (6) · Brain Neoplasms (5) · Melanoma (5) · Salivary Gland Neoplasms (5) · Stomach Neoplasms (5) · Carcinoma, Hepatocellular (4) · Inflammatory Breast Neoplasms (4) · Pancreatic Neoplasms (4) · Prostatic Neoplasms (4)
Breast Diseases (80) · Neoplasms (80) · Neoplasms by Site (80) · Skin Diseases (80) · Skin and Connective Tissue Diseases (80) · Neoplasms by Histologic Type (17) · Carcinoma (14) · Neoplasms, Glandular and Epithelial (14) · Urogenital Diseases (13) · Urogenital Neoplasms (13) · Adenocarcinoma (12) · Digestive System Diseases (12) · Digestive System Neoplasms (12) · Endocrine Gland Neoplasms (11) · Endocrine System Diseases (11)
Taxes (10) · Trastuzumab (10) · Paclitaxel (8) · Cyclophosphamide (7) · Vorinostat (6) · Doxorubicin (5) · Granulocyte-Macrophage Colony-Stimulating Factor (5) · Lapatinib (5) · N-(3-chloro-4-((3-fluorobenzyl)oxy)phenyl-6-(5-((methylsulfonyl)ethyl)aminomethyl)-2-furyl)-4-quinazolinamine (5) · sargramostim (5) · Anastrozole (4) · Tamoxifen (4) · Albumin-Bound Paclitaxel (3) · Bevacizumab (3) · Biopsy (3)
National Cancer Institute (NCI) (33) · University of Washington (14) · University of Chicago (3) · University of Arizona (2) · University of Southern California (2) · Wake Forest University Health Sciences (2) · Abramson Cancer Center at Penn Medicine (1) · Case Comprehensive Cancer Center (1) · Centro Hospitalar Lisboa Ocidental (1) · City of Hope Medical Center (1) · Fox Chase Cancer Center (1) · Fred Hutchinson Cancer Center (1) · GBG Forschungs GmbH (1) · H. Lee Moffitt Cancer Center and Research Institute (1) · Helios University Hospital Wuppertal (1)
United States (71) · Canada (2) · Germany (2) · France (1) · Netherlands (1) · Tunisia (1)
Lupe Salazar (5) · Hannah Linden (4) · Harold Burstein (3) · Jennifer Specht (3) · Mary Disis (2) · Massimo Cristofanilli (2) · Rita Nanda (2) · William Carson (2) · Agustin Garcia (1) · Alison Stopeck (1) · Amor Gamoudi, Pr (1) · Amy Degnim, M.D. (1) · Amye Tevaarwerk (1) · Antoinette Tan, MD (1) · Antonius Miller (1)
PMID 22200869, PMID 24068539, PMID 25965900, PMID 26006067, PMID 26059540, PMID 26062933, PMID 26611425, PMID 27190628, PMID 28114604, PMID 28764748, PMID 29239131, PMID 30542377, PMID 30850872, PMID 32641862, PMID 32692450, PMID 33538790, PMID 37946201
P30CA015704 (5), U10CA021115 (4), N01CM17003 (3), N01CM62204 (3), N01CM62209 (3), U01CA062490 (3), N01CM62205 (2), P30CA014520 (2), P30CA023074 (2), P50CA138293 (2), U01CA062491 (2), U01CA069856 (2), U01CA076576 (2), 2009 (1), N01CM00032 (1)